{"entity":{"id":"nct06083207","kind":"trial","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of IBI3003 in multiple myeloma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06083207 by Innovent Biologics (Suzhou) Co. Ltd., with 116 participants planned, started 2024-07-29 and due to reach its primary completion in 2026-10-31. Interventions recorded: IBI3003.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06083207","url":"https://clinicaltrials.gov/study/NCT06083207"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06083207","phase":"1/2","setting":"A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","started":"2024-07-29","startedType":"actual","enrolled":116,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06083207/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}